Prosecution Insights
Last updated: November 04, 2026
Application No. 18/703,300

NOVEL CANNABINOID DERIVATIVES

Non-Final OA §102§112
Filed
Apr 19, 2024
Priority
Nov 11, 2021 — IL 288042 +2 more
Examiner
SHIAO, YIH-HORNG
Art Unit
1691
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Cannasoul Analytics Ltd.
OA Round
1 (Non-Final)
73%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 73% — above average
73%
Career Allowance Rate
709 granted / 976 resolved
+12.6% vs TC avg
Strong +76% interview lift
Without
With
+75.9%
Interview Lift
resolved cases with interview
Typical timeline
2y 4m
Avg Prosecution
46 currently pending
Career history
1014
Total Applications
across all art units

Statute-Specific Performance

§101
6.2%
-33.8% vs TC avg
§103
33.7%
-6.3% vs TC avg
§102
16.4%
-23.6% vs TC avg
§112
28.7%
-11.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 976 resolved cases

Office Action

§102 §112
DETAILED ACTION The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Preliminary amendment filed on 04/19/2024 has been entered. Claims 1-48 are cancelled. Claims 49-68 are new and are pending in this application. Claims 57-68 are withdrawn. Claims 49-56 are currently under examination. Priority This application is a 371 of PCT/IL2022/051198 filed on 11/10/2022 and claims US PRO 63/308,089 filed on 02/09/2022 and foreign priority of ISRAEL 288042 filed on 11/11/2021. Receipt is acknowledged of certified copies of papers required by 37 CFR 1.55. Applicant’s claim for the benefit of a prior-filed application under 35 U.S.C. 119(e) or under 35 U.S.C. 120, 121, 365(c), or 386(c) is acknowledged. Applicant has not complied with one or more conditions for receiving the benefit of an earlier filing date under 35 U.S.C. 119(e), 365(c), or 386(c) as follows: The later-filed application must be an application for a patent for an invention which is also disclosed in the prior application (the parent or original nonprovisional application or provisional application). The disclosure of the invention in the parent application and in the later-filed application must be sufficient to comply with the requirements of 35 U.S.C. 112(a) or the first paragraph of pre-AIA 35 U.S.C. 112, except for the best mode requirement. See Transco Products, Inc. v. Performance Contracting, Inc., 38 F.3d 551, 32 USPQ2d 1077 (Fed. Cir. 1994). The disclosure of the prior-filed application, Application No. 63/308,089 or ISRAEL 288042, fails to provide adequate support or enablement in the manner provided by 35 U.S.C. 112(a) or pre-AIA 35 U.S.C. 112, first paragraph for one or more claims of this application. Claims 49-56 recite “R2 is… deuterium… R3 is… deuterium… R4 is… deuterium… or unsubstituted C(O)C1-C4 alkyl; R5 is… deuterium… each of the alkyl, alkenyl, alkynyl, cyclyl, aryl, acyl, amino or amido is optionally deuterated… R1 is not… 2-phenylethyl”, “R3 is… C(O)OCD3”, “R3 is C(O)OCD3”, and/or “ PNG media_image1.png 200 400 media_image1.png Greyscale , which are not disclosed or supported by the prior-filed ISRAEL 288042. Also, the recitations “R4 is… unsubstituted C(O)C1-C4 alkyl… R1 is not… 2-phenylethyl” of claims 49-56 are not disclosed or supported by the prior-filed Application No. 63/308,089. Thus, the priority date of claims 49-56 is 11/10/2022. Election/Restrictions Applicant's election without traverse of Group I invention (claims 49-56) and species (the compound of formula 12 encompassed by the structure of formula I when R1 is pentyl; R2 is H; R3 is C(O)OCH3; R4 is H; R5 is methyl, and the dotted line represents a second carbon-carbon bond) in the reply filed on 09/11/2026 is acknowledged. Claims 57-68 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention or species, there being no allowable generic or linking claim. Thus, claims 49-56 are currently under examination. Information Disclosure Statement Two information disclosure statement (IDS) filed on 08/6/2024 and 09/11/2026 have been considered. Claim Objections Claims 49, 55, and 56 are objected to because of the following informalities: In claim 49, change the incorrect recitations “represented by” (line 1) and “represents” (last paragraph on page 3, a total of 2 occurrences), which means one of many, to “having” and “is”, respectively; and replace the incorrect recitation “including salts” (line 1 on page 4) with “wherein the compound is optionally salts” because “salts” is one genus of the compound, not species of formula I. In claim 55, change the incorrect recitation “represents” (a total of 12 occurrences), which means one of many, to “is”. In claim 56, insert the missing phrase “wherein the compound is” immediately before the recitation “selected from” (line 1) to become proper dependent claim format; provide legible chemical structures of the blurry compounds 13 and 14; and change the incorrect recitation “including salts” (2nd line from the end of the claim) to “, salts”. Appropriate correction is required. Claims 49 and 56 are objected to because they include reference characters which are not enclosed within parentheses. Reference characters corresponding to elements recited in the detailed description of the drawings and used in conjunction with the recitation of the same element or group of elements in the claims should be enclosed within parentheses so as to avoid confusion with other numbers or characters which may appear in the claims. See MPEP § 608.01(m). Applicant is advised to insert parenthesis for the Roman number “I” (claim 49) and the numbers “1”, “2”, “3”, “4”, “5”, “6”, “7”, “8”, “9”, “10,”, “11”, “12”, “13”, “14”, “15”, “16,”, “17”, “18”, “19”, “20”, “21”, “22”, “23”, “24”, “25”, “26”, “27”, “28”, “29”, “30”, “31”, “32”, “33”, “34,”, “35”, “36”, and “37” (claim 56) immediately underneath of the corresponding chemical structures. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 49-56 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claims 50-55 depend from claim 49. A broad range or limitation together with a narrow range or limitation that falls within the broad range or limitation (in the same claim) may be considered indefinite if the resulting claim does not clearly set forth the metes and bounds of the patent protection desired. See MPEP § 2173.05(c). In the present instance, claims 49 and 56 recites the broad recitation “optical isomers”, and the claim also recites “enantiomers, diastereomers… and mixtures thereof” which is the narrower statement of the range/limitation. The claim(s) are considered indefinite because there is a question or doubt as to whether the feature introduced by such narrower language is (a) merely exemplary of the remainder of the claim, and therefore not required, or (b) a required feature of the claims. Applicant is advised to change the recitation “and mixtures thereof” (last line of claim 49) to “or mixtures of distinct compounds thereof”; and to replace the recitation “mixtures thereof” (last line of claim 56” with “mixtures of distinct compounds thereof”. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. (I) Claims 49-56 are rejected under 35 U.S.C. 102(a)(1) or 102(a)(2) as being anticipated by Zhou et al. (WO2021/139741, published on July 15, 2021, PCT filed on January 07, 2021, and provided with English from US 2023/0059087 for citation here, hereinafter referred to as Zhou ‘741, also listed in IDS filed on 08/06/2024). With regard to structural limitations “A compound having the structure of Formula I: PNG media_image2.png 200 400 media_image2.png Greyscale wherein R1 is pentyl; R2 is H; R3 is COOH; R4 is H; R5 is methyl, and the dotted line is a second carbon-carbon bond (= compound 11: PNG media_image3.png 200 400 media_image3.png Greyscale ; or elected compound of formula 12: PNG media_image4.png 200 400 media_image4.png Greyscale , wherein R1 is pentyl; R2 is H; R3 is C(O)OCH3; R4 is H; R5 is methyl, and the dotted line is a second carbon-carbon bond, in which an “alkyl” group refers to any unsubstituted or substituted alkyl, defined in the Specification, p. 17, line 17)” (claims 49-56): Zhou ‘741 disclosed an Intermediate compound 5b: PNG media_image5.png 329 554 media_image5.png Greyscale and an Intermediate compound 23: PNG media_image6.png 200 400 media_image6.png Greyscale (pages 17/41 and 31/41). Thus, these teachings of Zhou ‘741 anticipate Applicant’s claims 49-56 because the claimed methyl of R5 encompasses substituted methyl and thus the CD3 (D = deuterium) of Zhou ‘741. (II) Claims 49-56 are rejected under 35 U.S.C. 102(a)(1) or 102(a)(2) as being anticipated by Pang et al. (CN115197051A, published on 2022-10-18, and provided with English translation from Google Patents for citation here, hereinafter referred to as Pang ‘051). With regard to structural limitations “A compound having the structure of Formula I: PNG media_image2.png 200 400 media_image2.png Greyscale wherein R1 is hexyl; R2 is H; R3 is H; R4 is H; R5 is methyl, and the dotted line is a second carbon-carbon bond (= compound 1: PNG media_image7.png 198 383 media_image7.png Greyscale ); or wherein R1 is butyl; R2 is H; R3 is H; R4 is H; R5 is methyl, and the dotted line is a second carbon-carbon bond (= compound 6: PNG media_image8.png 207 334 media_image8.png Greyscale )” (claims 49-56): Pang ‘051 disclosed a compound IV2: PNG media_image9.png 200 400 media_image9.png Greyscale and a compound IV3: PNG media_image10.png 842 1198 media_image10.png Greyscale (page 4/31). Thus, these teachings of Pang ‘051 anticipate Applicant’s claims 49-56. Conclusion No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to YIH-HORNG SHIAO whose telephone number is (571)272-7135. The examiner can normally be reached Mon-Thur, 08:30 am to 07:00 pm EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Renee Claytor can be reached at 571-272-8394. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /YIH-HORNG SHIAO/Primary Examiner, Art Unit 1691
Read full office action

Prosecution Timeline

Apr 19, 2024
Application Filed
Oct 19, 2026
Non-Final Rejection mailed — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12781216
IMPROVED REMOVAL OF RNA AND CONTAMINANTS FROM DNA PLASMID PREPARATIONS BY HYDROPHOBIC INTERACTION CHROMATOGRAPHY
3y 7m to grant Granted Nov 03, 2026
Patent 12779086
WOUND DRESSING COMPRISING HYALURONIC ACID-CALCIUM AND POLYLYSINE AND MANUFACTURING METHOD THEREFOR
2y 12m to grant Granted Nov 03, 2026
Patent 12778971
COMPOSITIONS AND METHODS FOR TREATMENT OF MITOCHONDRIAL RESPIRATORY CHAIN DYSFUNCTION AND OTHER MITOCHONDRIAL DISORDERS
2y 11m to grant Granted Nov 03, 2026
Patent 12751470
Use Of Ionic Polymers In Biomass Processing For Preparation Of Animal Feed Additive
4y 2m to grant Granted Oct 06, 2026
Patent 12751909
COSMETIC PREPARATION
3y 2m to grant Granted Oct 06, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
73%
Grant Probability
99%
With Interview (+75.9%)
2y 4m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 976 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month